MARKET

DICE

DICE

Dice Therapeutics, Inc.
NASDAQ
32.56
-0.91
-2.72%
Closed 13:01 11/25 EST
OPEN
33.54
PREV CLOSE
33.47
HIGH
33.85
LOW
32.25
VOLUME
93.42K
TURNOVER
0
52 WEEK HIGH
45.99
52 WEEK LOW
12.64
MARKET CAP
1.55B
P/E (TTM)
-15.9047
1D
5D
1M
3M
1Y
5Y
Where DICE Therapeutics Stands With Analysts
Benzinga · 11/15 16:23
Guggenheim Initiates Coverage On DICE Therapeutics with Buy Rating, Announces Price Target of $65
Benzinga · 11/15 12:32
Blue Star (NASDAQ: BSFC) Insiders Are Buying Stock
Benzinga · 11/11 13:41
DICE Therapeutics GAAP EPS of -$0.55 beats by $0.05
Seekingalpha · 11/09 22:22
DICE Therapeutics Q3 EPS $(0.55) Up From $(2.15) YoY
Benzinga · 11/09 22:15
-- Earnings Flash (DICE) DICE THERAPEUTICS Reports Q3 Loss $-0.55
-- Earnings Flash (DICE) DICE THERAPEUTICS Reports Q3 Loss $-0.55
MT Newswires · 11/09 16:11
DICE Therapeutics to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic dise...
GlobeNewswire · 11/03 20:05
Candel, Calliditas top healthcare gainers; Immunic, Tenet lead losers pack
Seekingalpha · 10/21 14:00
More
About DICE
DICE Therapeutics, Inc., formerly Dice Molecules Holdings LLC, is a biopharmaceutical company. The Company leverages its technology platform to build a pipeline of oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. It is focused on developing oral therapeutics against targets in immunology. The Company’s platform, which it refers to as DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. Its lead therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. The Company is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF).

Webull offers kinds of Dice Therapeutics Inc stock information, including NASDAQ:DICE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DICE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DICE stock methods without spending real money on the virtual paper trading platform.